前列地尔联合注射用胰激肽原酶治疗早期糖尿病足的效果

Pancreatic Kininogenase for Injection and Alprostadil Treatment of Early Diabetic Foot Effect

目的探究早期糖尿病足患者采用前列地尔和胰激肽原酶联合治疗效果。方法选取该院从2015年5月—2017年5月所收治的50例早期糖尿病足患者作为该研究的对象,将患者分为治疗组和常规组,每组25例患者,常规组患者采用前列地尔进行治疗,而治疗组则在基础上联合胰激肽原酶实施治疗,比较两组患者的治疗效果。结果治疗组患者的效果优于常规组,差异有统计学意义(P<0.05)。结论早期糖尿病足患者采用前列地尔和胰激肽原酶联合治疗取得良好的效果,值得运用和推广。

Objective To explore the early diabetic foot treated with Alprostadil Combined with kallidinogenase treatment. Methods 50 cases of early diabetic foot patients in our hospital from May 2015 to May 2017 were as the research object, the patients were divided into treatment group and routine group, 25 patients in each group. The routine group were treated with Alprostadil for treatment, while the treatment group on the basis of the combination of Kallidinogenase treatment. The therapeutic effect of two groups. Results The normal group is better than the patients in the treatment group, significant difference(P <0.05), there was statistical significance. Conclusion Early diabetic foot Patients were treated with Alprostadil Combined with kallidinogenase treatment has a good effect, worthy of application and promotion.